Results for this period
First quarter1 June 2026 to 31 August 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In the pharmaceuticals business, sales of imported active pharmaceutical ingredients increased against a backdrop of growing demand for existing products. In the chemicals business, sales of ion-exchange resins, in-house processed products, in-house manufactured equipment and purified amino acids increased against a backdrop of increased activity in the semiconductor-related market.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 June 2026 to 31 August 2026 |
| Net Sales | ¥1,861 million (YoY +4.1%) |
| Operating profit | ¥182 million (YoY +144.8%) |
| Ordinary income | ¥191 million (YoY +161.9%) |
| Profit attributable to owners of the parent | ¥142 million (YoY +147.5%) |
| Net income per share | ¥35.32 |
| Equity ratio | End of the current fiscal period 45.6 / End of previous period 40.6 |
| Total assets | ¥5,867 million |
| Net assets | ¥2,677 million |
| Full-year earnings forecast | Net Sales ¥7,100 million (YoY -9.4%) / Operating profit ¥550 million (YoY -26.0%) / Ordinary income ¥500 million (YoY -29.3%) / Net income ¥350 million (YoY +114.7%) |
| Revision to Earnings Forecast | Not disclosed → Second quarter (cumulative) Net Sales 3,500 / Operating profit 250 / Ordinary income 240 / Net income 160 |
| Annual Dividend Forecast | ¥26 → ¥26（0.0%） |
| Segment revenue | Pharmaceuticals Business ¥1,068,639 thousand (YoY +21.7%), Chemicals Business ¥792,489 thousand (YoY +30.8%) |
| Segment profit | Pharmaceuticals Business ¥141,600 thousand (YoY +61.0%), Chemicals Business ¥41,040 thousand (YoY +399.0%) |
| Depreciation and amortization | ¥27,015 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | On 9 October 2026, the company disposed of 20,000 treasury shares as restricted stock compensation at ¥871 per share, for a total disposal amount of ¥17,420,000. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 4,095,500 |
| Treasury Shares at Period-End | 69,926 |
| Factors Behind Changes in Business Performance | In the pharmaceuticals business, sales of imported active pharmaceutical ingredients increased against a backdrop of growing demand for existing products. In the chemicals business, sales of ion-exchange resins, in-house processed products, in-house manufactured equipment and purified amino acids increased against a backdrop of increased activity in the semiconductor-related market. |
| Reason for Revision of Earnings Forecast | The company revised its interim earnings forecast in light of recent performance trends and other factors. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the pharmaceuticals business, sales of imported active pharmaceutical ingredients increased. In the chemicals business, sales of ion-exchange resins, in-house processed products, in-house manufactured equipment and purified amino acids increased against a backdrop of increased activity in the semiconductor-related market. The company stated that it also worked on developing new products, entering new fields and improving production efficiency. It said the revision to its earnings forecast was made “in light of recent performance trends and other factors.”